Neuromuscular DiseasesNeuromuscular DiseasesНервно-мышечные болезни2222-87212413-0443Publishing House ABV Press7610.17650/2222-8721-2012-0-2-20-28LECTURES AND REVIEWSЛЕКЦИИ И ОБЗОРЫДисферлинопатии: проблема за пределами дистальных миопатийUrtizbereaJ. AndoniRussian Federationandoni.urtizberea@hnd.aphp.frГоспиталь Марэн Андэ200420122220282002201520022015Copyright ©; 2012, .Copyright ©; 2012, Urtizberea J.2012.Urtizberea J.https://creativecommons.org/licenses/by/4.0https://nmb.abvpress.ru/jour/article/view/76дисферлинопатиидисферлинмиопатия Миошидистальная миопатиядистальная миопатия с первичным поражением переднего ложа голениLGMD 2Bмышечная дистрофиямембранная репарацияминидисферлин[1. Miyoshi K., Jap J. Hum Genet 1967;12:113Miyoshi K., Jap J. Hum Genet 1967;12:113][2. Miyoshi K., Kawai H., Iwasa M. et al. Autosomal recessive distal muscular dystrophy as a new type of progressive muscular dystrophy. Seventeen cases in eight families including an autopsied case. Brain 1986;109:31−54.Miyoshi K., Kawai H., Iwasa M. et al. Autosomal recessive distal muscular dystrophy as a new type of progressive muscular dystrophy. Seventeen cases in eight families including an autopsied case. Brain 1986;109:31−54.][3. Bashir R., Britton S., Strachan T. et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer‑1 is mutated in limb‑girdle muscular dystrophy type 2B. Nat Genet 1998;20:37−42.Bashir R., Britton S., Strachan T. et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer‑1 is mutated in limb‑girdle muscular dystrophy type 2B. Nat Genet 1998;20:37−42.][4. Liu J., Aoki M., Illa I. et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 1998;20: 31−6.Liu J., Aoki M., Illa I. et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 1998;20: 31−6.][5. Illa I., Serrano‑Munuera C., Gallardo E. et al. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 2001;49:130–4.Illa I., Serrano‑Munuera C., Gallardo E. et al. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 2001;49:130–4.][6. Nguyen K., Bassez G., Krahn M. et al. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 2007;64:1176−82.Nguyen K., Bassez G., Krahn M. et al. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 2007;64:1176−82.][7. Aoki M., Liu J., Richard I. et al. Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. Neurology 2001;57:271−8.Aoki M., Liu J., Richard I. et al. Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. Neurology 2001;57:271−8.][8. Diers A., Carl M., Stoltenburg‑Didinger G. et al. Painful enlargement of the calf muscles in limb girdle muscular dystrophy type 2B (LGMD2B) with a novel compound heterozygous mutation in DYSF. Neuromuscul Disord 2007;17:157−62.Diers A., Carl M., Stoltenburg‑Didinger G. et al. Painful enlargement of the calf muscles in limb girdle muscular dystrophy type 2B (LGMD2B) with a novel compound heterozygous mutation in DYSF. Neuromuscul Disord 2007;17:157−62.][9. Eymard B., Laforêt P., Tomé F.M. et al. Miyoshi distal myopathy: specific signs and incidence. Rev Neurol (Paris) 2000;156:161−8.Eymard B., Laforêt P., Tomé F.M. et al. Miyoshi distal myopathy: specific signs and incidence. Rev Neurol (Paris) 2000;156:161−8.][10. Weiler T., Greenberg C.R., Nylen E. et al. Limb‑girdle muscular dystrophy and Miyoshi myopathy in an aboriginal Canadian kindred map to LGMD2B and segregate with the same haplotype. Am J Hum Genet 1996;59:873−8.Weiler T., Greenberg C.R., Nylen E. et al. Limb‑girdle muscular dystrophy and Miyoshi myopathy in an aboriginal Canadian kindred map to LGMD2B and segregate with the same haplotype. Am J Hum Genet 1996;59:873−8.][11. Illarioshkin S.N., Ivanova‑Smolenskaya I.A., Tanaka H. et al. Clinical and molecular analysis of a large family with three distinct phenotypes of progressive muscular dystrophy. Brain 1996;119:1895−909.Illarioshkin S.N., Ivanova‑Smolenskaya I.A., Tanaka H. et al. Clinical and molecular analysis of a large family with three distinct phenotypes of progressive muscular dystrophy. Brain 1996;119:1895−909.][12. Fanin M., Nascimbeni A.C., Aurino S. et al. Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Neurology 2009;72:1432−5.Fanin M., Nascimbeni A.C., Aurino S. et al. Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Neurology 2009;72:1432−5.][13. Paradas C., González‑Quereda L., De Luna N. et al. A new phenotype of dysferlinopathy with congenital onset. Neuromuscul Disord 2009;19:21–5.Paradas C., González‑Quereda L., De Luna N. et al. A new phenotype of dysferlinopathy with congenital onset. Neuromuscul Disord 2009;19:21–5.][14. Wenzel K., Geier C., Qadri F. et al. Dysfunction of dysferlin-deficient hearts. J Mol Med 2007;85:1203−14.Wenzel K., Geier C., Qadri F. et al. Dysfunction of dysferlin-deficient hearts. J Mol Med 2007;85:1203−14.][15. Paradas C., Llauger J., Diaz‑Manera J. et al. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology 2010;75:298−9.Paradas C., Llauger J., Diaz‑Manera J. et al. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology 2010;75:298−9.][16. Spuler S., Carl M., Zabojszcza J., et al. Dysferlin-deficient muscular dystrophy features amyloidosis. Ann Neurol 2008; 63(3):323−8.Spuler S., Carl M., Zabojszcza J., et al. Dysferlin-deficient muscular dystrophy features amyloidosis. Ann Neurol 2008; 63(3):323−8.][17. Rosales X.Q., Gastier‑Foster J.M., Lewis S. et al. Novel diagnostic features of dysferlinopathies. Muscle Nerve 2010;42:14−21.Rosales X.Q., Gastier‑Foster J.M., Lewis S. et al. Novel diagnostic features of dysferlinopathies. Muscle Nerve 2010;42:14−21.][18. Kawabe K., Goto K., Nishino I. et al. Dysferlin mutation analysis in a group of Italian patients with limb‑girdle muscular dystrophy and Miyoshi myopathy. Eur J Neurol 2004;11:657−61.Kawabe K., Goto K., Nishino I. et al. Dysferlin mutation analysis in a group of Italian patients with limb‑girdle muscular dystrophy and Miyoshi myopathy. Eur J Neurol 2004;11:657−61.][19. Krahn M., Beroud C., Labelle V. et al. Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat 2009;30:E345−75.Krahn M., Beroud C., Labelle V. et al. Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat 2009;30:E345−75.][20. Bansal D., Miyake K., Vogel S.S. et al. Defective membrane repair in dysferlindeficient muscular dystrophy. Nature 2003; 423:168−72.Bansal D., Miyake K., Vogel S.S. et al. Defective membrane repair in dysferlindeficient muscular dystrophy. Nature 2003; 423:168−72.][21. De Morrée A., Hensbergen P.J., van Haagen H.H. et al. Proteomic analysis of the dysferlin protein complex unveils its importance for sarcolemmal maintenance and integrity. PLoS One 2010; 5:e13854.De Morrée A., Hensbergen P.J., van Haagen H.H. et al. Proteomic analysis of the dysferlin protein complex unveils its importance for sarcolemmal maintenance and integrity. PLoS One 2010; 5:e13854.][22. Linssen W.H., Notermans N.C., Van der Graaf Y. et al. Miyoshi‑type distal muscular dystrophy. Clinical spectrum in 24 Dutch patients. Brain 1997;120:1989−96.Linssen W.H., Notermans N.C., Van der Graaf Y. et al. Miyoshi‑type distal muscular dystrophy. Clinical spectrum in 24 Dutch patients. Brain 1997;120:1989−96.][23. Hicks D., Sarkozy A., Muelas N. et al. A founder mutation in Anoctamin 5 is a major cause of limb‑girdle muscular dystrophy. Brain 2011;134:171−82.Hicks D., Sarkozy A., Muelas N. et al. A founder mutation in Anoctamin 5 is a major cause of limb‑girdle muscular dystrophy. Brain 2011;134:171−82.][24. Rawat R., Cohen T.V., Ampong B., et al. Inflammasome up‑regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol 2010;176:2891−900.Rawat R., Cohen T.V., Ampong B., et al. Inflammasome up‑regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol 2010;176:2891−900.][25. Krahn M., Wein N., Bartoli M. et al. A naturally occurring human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dysferlinopathy. Sci Transl Med 2010;2:50−69.Krahn M., Wein N., Bartoli M. et al. A naturally occurring human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dysferlinopathy. Sci Transl Med 2010;2:50−69.][26. Han R., Frett E.M., Levy J.R. et al. Genetic ablation of complement C3 attenuates muscle pathology in dysferlindeficient mice. J Clin Invest 2010; 120(12):4366−74,Han R., Frett E.M., Levy J.R. et al. Genetic ablation of complement C3 attenuates muscle pathology in dysferlindeficient mice. J Clin Invest 2010; 120(12):4366−74,][27. Choi E.R., Choi E.R., Park S.J. et al. Early detection of cardiac involvement in Miyoshi myopathy: 2D strain echocardiography and late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010;2:12−31.Choi E.R., Choi E.R., Park S.J. et al. Early detection of cardiac involvement in Miyoshi myopathy: 2D strain echocardiography and late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010;2:12−31.]